๐๏ธ Verified NIH Record โข Updated 2026-07-22
Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML (NCT06580106)
๐ข Recruiting Interventional Protocol ๐ Observational Clinical Research Sponsor: Wake Forest University Health Sciences
๐ฉบ Plain-English Summary (8th-Grade Level)
The purpose of this research is to see how certain genetic variations relate to side effects and outcomes experienced while receiving treatment with azacitidine and venetoclax.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (6 items) and avoid the listed exclusions (1 items).
Location: Levine Cancer Institute โ Charlotte, North Carolina
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
๐ Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
๐ All Participating Trial Locations (2 Sites)
- Levine Cancer Institute โ Charlotte, North Carolina
- Wake Forest Baptist Comprehensive Cancer Center โ Winston-Salem, North Carolina
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.